nach oben

Erschienen in:

01.02.2016 | Review

Diabetes mellitus and gynecologic cancer: molecular mechanisms, epidemiological, clinical and prognostic perspectives

verfasst von: Nikolaos Vrachnis, Christos Iavazzo, Zoe Iliodromiti, Stavros Sifakis, Andreas Alexandrou, Charalambos Siristatidis, Charalambos Grigoriadis, Dimitrios Botsis, George Creatsas

Erschienen in: Archives of Gynecology and Obstetrics | Ausgabe 2/2016

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Diabetes mellitus, the prevalence of which has increased dramatically worldwide, may put patients at a higher risk of cancer. The aim of our study is the clarification of the possible mechanisms linking diabetes mellitus and gynecological cancer and their epidemiological relationship.

Materials and Methods

This is a narrative review of the current literature, following a search on MEDLINE and the Cochrane Library, from their inception until January 2012. Articles investigating gynecologic cancer (endometrial, ovarian, and breast) incidence in diabetic patients were extracted.

Results

The strong evidence for a positive association between diabetes mellitus and the risk for cancer indicates that energy intake in excess to energy expenditure, or the sequelae thereof, is involved in gynecological carcinogenesis. This risk may be further heightened by glucose which can directly promote the production of tumor cells by functioning as a source of energy. Insulin resistance accompanied by secondary hyperinsulinemia is hypothezised to have a mitogenic effect. Steroid hormones are in addition potent regulators of the balance between cellular differentiation, proliferation, and apoptosis. Inflammatory pathways may also be implicated, as a correlation seems to exist between diabetes mellitus and breast or endometrial carcinoma pathogenesis, although an analogous correlation with ovarian carcinoma is still under investigation. Antidiabetic agents have been correlated with elevated cancer risk, while metformin seems to lower the risk.

Conclusion

Diabetes mellitus is associated with an elevation in gynecologic cancer risk. Moreover, there are many studies exploring the prognosis of patients with diabetes and gynecological cancer, the outcome and the overall survival in well-regulated patients.

Pollak M (2010) Metformin and other biguanides in oncology: advancing the research agenda. Cancer Prev Res 3:1060–1065CrossRef

Brownlee M (2005) The pathobiology of diabetic complications: a unifying mechanism. Diabetes 54:1615–1625PubMedCrossRef

Hirsch HA, Iliopoulos D, Tsichlis PN, Struhl K (2009) Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res 69:7507–7511PubMedPubMedCentralCrossRef

Abdel-Hamid NM, Nazmy MH, Abdel-Ghany MI, Nazmy WH (2012) Cytokines as important playmakers of experimental hepatocarcinogenesis confounded by diabetes. Ann Hepatol 11:118–127PubMed

Zhong Y, Li J, Chen Y, Wang J et al (2012) Activation of endoplasmic reticulum stress by hyperglycemia is essential for muller cell-derived inflammatory cytokine production in diabetes. Diabetes 61:492–504PubMedPubMedCentralCrossRef

Di Bartolo BA, Chan J, Bennett MR et al (2012) TNF-related apoptosis-inducing ligand (TRAIL) protects against diabetes and atherosclerosis in Apoe−/− mice. Diabetologia 54:3157–3167CrossRef

Geraldes P, King GL (2010) Activation of protein kinase C isoforms and its impact on diabetic complications. Circ Res 106:1319–1331PubMedPubMedCentralCrossRef

Zhu W, Jia Q, Wang Y et al (2012) The anthocyanin cyanidin-3-O-β-glucoside, a flavonoid, increases hepatic glutathione synthesis and protects hepatocytes against reactive oxygen species during hyperglycemia: involvement of a cAMP-PKA-dependent signaling pathway. Free Radic Biol Med 52:314–327PubMedCrossRef

Schultze SM, Hemmings BA, Niessen M, Tschopp O (2012) PI3K/AKT, MAPK and AMPK signalling: protein kinases in glucose homeostasis. Expert Rev Mol Med 11(14):e1CrossRef

10.

Balkwill F, Mantovani A (2001) Inflammation and cancer: back to Virchow? Lancet 357:539–545PubMedCrossRef

11.

Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420:860–867PubMedPubMedCentralCrossRef

12.

Gapstur SM, Gann PH, Lowe W et al (2000) Abnormal glucose metabolism and pancreatic cancer mortality. JAMA 283:2552–2558PubMedCrossRef

13.

Xue F, Michels KB (2007) Diabetes, metabolic syndrome, and breast cancer: a review of the current evidence. Am J Clin Nutr 86:823–835

14.

Hjartåker A, Langseth H, Weiderpass E (2008) Obesity and diabetes epidemics: cancer repercussions. Adv Exp Med Biol 630:72–93PubMedCrossRef

15.

Liao DJ, Dickson RB (2002) Roles of androgens in the development, growth, and carcinogenesis of the mammary gland. J Steroid Biochem Mol Biol 80:175–189PubMedCrossRef

16.

Ross RK, Paganini-Hill A, Wan PC, Pike MC (2000) Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst 92:328–332PubMedCrossRef

17.

Key TJ (1999) Serum oestradiol and breast cancer risk. Endocr Relat Cancer 6:175–180PubMedCrossRef

18.

Cho LW, Kilpatrick ES, Keevil BG et al (2011) Insulin resistance variability in women with anovulatory and ovulatory polycystic ovary syndrome, and normal controls. Horm Metab Res 43:141–145PubMedCrossRef

19.

Persson I, Weiderpass E, Bergkvist L et al (1999) Risks of breast and endometrial cancer after estrogen and estrogen-progestin replacement. Cancer Causes Control 10:253–260PubMedCrossRef

20.

Rutanen EM (1998) Insulin-like growth factors in endometrial function. Gynecol Endocrinol 12:399–406PubMedCrossRef

21.

Lukanova A, Lundin E, Micheli A et al (2004) Circulating levels of sex steroid hormones and risk of endometrial cancer in postmenopausal women. Int J Cancer 108:425–432PubMedCrossRef

22.

Risch HA (1998) Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone. J Natl Cancer Inst 90:1774–1786PubMedCrossRef

23.

Kaaks R (1996) Nutrition, hormones, and breast cancer: Is insulin the missing link? Cancer Causes Control 7:605–625PubMedCrossRef

24.

Wolf I, Sadetzki S, Catane R et al (2005) Diabetes mellitus and breast cancer. Lancet Oncol 6:103–111PubMedCrossRef

25.

Khandwala HM, McCutcheon IE, Flyvbjerg A, Friend KE (2000) The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr Rev 21:215–244PubMedCrossRef

26.

Kluge A, Zimmermann R, Munkel B et al (1995) Insulin-like growth factor I is involved in inflammation linked angiogenic processes after microembolisation in porcine heart. Cardiovasc Res 29:407–415PubMedCrossRef

27.

Becker S, Dossus L, Kaaks R (2009) Obesity related hyperinsulinaemia and hyperglycaemia and cancer development. Arch Physiol Biochem 115:86–96PubMedCrossRef

28.

Nestler JE (2000) Obesity, insulin, sex steroids and ovulation. Int J Obes Relat Metab Disord 24:71–73CrossRef

29.

Kaaks R, Lukanova A (2001) Energy balance and cancer: the role of insulin and insulin-like growth factor-I. Proc Nutr Soc 60:91–106PubMedCrossRef

30.

Ramasamy R, Yan SF, Schmidt AM (2009) RAGE: therapeutic target and biomarker of the inflammatory response the evidence mounts. J Leukoc Biol 86:505–512PubMedCrossRef

31.

Jemal A, Tiwari CG, Murray T et al (2004) Cancer statistics. Cancer J Clin 54:8–29CrossRef

32.

Coughlin SS, Calle EE, Teras LR et al (2004) Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. Am J Epidemiol 159:1160–1167PubMedCrossRef

33.

Friberg E, Orsini N, Mantzoros CS, Wolk A (2007) Diabetes mellitus and risk of endometrial cancer: a meta-analysis. Diabetologia 50:1365–1374PubMedCrossRef

34.

Salazar-Martinez E, Lazcano-Ponce EC, Lira-Lira GG et al (2000) Case-control study of diabetes, obesity, physical activity and risk of endometrial cancer among Mexican women. Cancer Causes Control 11:707–711PubMedCrossRef

35.

Xu WH, Matthews CE, Xiang YB et al (2005) Effect of adiposity and fat distribution on endometrial cancer risk in Shanghai women. Am J Epidemiol 161:939–947PubMedCrossRef

36.

Berstein LM, Kvatchevskaya JO, Poroshina TE et al (2004) Insulin resistance, its consequences for the clinical course of the disease, and possibilities of correction in endometrial cancer. J Cancer Res Clin Oncol 130:687–693PubMedCrossRef

37.

Gnacinska M, Malgorzewicz S, Stojek M et al (2009) Role of adipokines in complications related to obesity: a review. Adv Med Sci 54:150–157PubMedCrossRef

38.

Hanley AJ, Bowden D, Wagenknecht LE et al (2007) Associations of adiponectin with body fat distribution and insulin sensitivity in nondiabetic Hispanics and African-Americans. J Clin Endocrinol Metab 92:2665–2671PubMedCrossRef

39.

Finucane FM, Luan J, Wareham NJ et al (2009) Correlation of the leptin: adiponectin ratio with measures of insulin resistance in non-diabetic individuals. Diabetologia 52:2345–2349PubMedPubMedCentralCrossRef

40.

Ashizawa N, Yahata T, Quan J, Adachi S, Yoshihara K, Tanaka K (2010) Serum leptin–adiponectin ratio and endometrial cancer risk in postmenopausal female subjects. Gynecol Oncol 119:65–69PubMedCrossRef

41.

Dal Maso L, Augustin LS, Karalis A et al (2004) Circulating adiponectin and endometrial cancer risk. J Clin Endocrinol Metab 89:1160–1163PubMedCrossRef

42.

Painter JN, O’Mara TA, Batra J et al (2015) Fine-mapping of the HNF1B multicancer locus identifies candidate variants that mediate endometrial cancer risk. Hum Mol Genet 24:1478–1492PubMedPubMedCentralCrossRef

43.

Spurdle AB, Thompson DJ, Ahmed S et al (2011) Genome-wide association study identifies a common variant associated with risk of endometrial cancer. Nat Genet 43:451–454PubMedPubMedCentralCrossRef

44.

Gogas H, Shapiro F, Aghajanian C et al (1996) The impact of diabetes mellitus on the toxicity of therapy for advanced ovarian cancer. Gynecol Oncol 61:22–26PubMedCrossRef

45.

Fasching PA, Gayther S, Pearce L et al (2009) Role of genetic polymorphisms and ovarian cancer susceptibility. Mol Oncol 2:171–181CrossRef

46.

Lee AW, Tyrer JP, Doherty JA et al (2015) Evaluating the ovarian cancer gonadotropin hypothesis: a candidate gene study. Gynecol Oncol 136:542–548PubMedCrossRef

47.

Parazzini F, Moroni S, La Vecchia C et al (1997) Ovarian cancer risk and history of selected medical conditions linked with female hormones. Eur J Cancer 33:1634–1637PubMedCrossRef

48.

Weiderpass E, Ye W, Vainio H et al (2002) Diabetes mellitus and ovarian cancer. Cancer Causes Control 13:759–764PubMedCrossRef

49.

Hemminki K, Li X, Sundquist J, Sundquist K (2010) Risk of cancer following hospitalization for type 2 diabetes. Oncologist 15:548–555PubMedPubMedCentralCrossRef

50.

Bakhru A, Buckanovich R, Griggs J (2011) The impact of diabetes on survival in women with ovarian cancer. Gynecol Oncol 121:106–111PubMedCrossRef

51.

Bordeleau L, Lipscombe L, Lubinski J, Hereditary Breast Cancer Clinical Study Group et al (2011) Diabetes and breast cancer among women with BRCA1 and BRCA2 mutations. Cancer 117:1812–1818PubMedPubMedCentralCrossRef

52.

Yakar S, Pennisi P, Zhao H, et al (2004) Circulating IGF-1 and its role in cancer: lessons from the IGF-1 gene deletion (LID) mouse. Novartis Found Symp 262:3–9 (discussion 9–18, 265–268)

53.

Seldin DC, Landesman-Bollag E, Farago M et al (2005) CK2 as a positive regulator of Wnt signalling and tumourigenesis. Mol Cell Biochem 274:63–67PubMedCrossRef

54.

Wideroff L, Gridley G, Mellemkjaer L et al (1989) Cancer incidence in a population-based cohort of patients hospitalized with diabetes mellitus in Denmark. J Natl Cancer Inst 89:1360–1365CrossRef

55.

Weiss HA, Brinton LA, Potischman NA et al (1999) Breast cancer risk in young women and history of selected medical conditions. Int J Epidemiol 28:816–823PubMedCrossRef

56.

Talamini R, Franceschi S, Favero A et al (1997) Selected medical conditions and risk of breast cancer. Br J Cancer 75:1699–1703PubMedPubMedCentralCrossRef

57.

Jee SH, Ohrr H, Sull JW et al (2005) Fasting serum glucose level and cancer risk in Korean men and women. JAMA 293:194–202PubMedCrossRef

58.

Rapp K, Schroeder J, Klenk J et al (2006) Fasting blood glucose and cancer risk in a cohort of more than 140,000 adults in Austria. Diabetologia 49:945–952PubMedCrossRef

59.

Stattin P, Bjor O, Ferrari P et al (2007) Prospective study of hyperglycemia and cancer risk. Diab Care 30:561–567CrossRef

60.

Mink PJ, Shahar E, Rosamond WD et al (2002) Serum insulin and glucose levels and breast cancer incidence: the atherosclerosis risk in communities study. Am J Epidemiol 156:349–352PubMedCrossRef

61.

Kabat GC, Kim M, Caan BJ et al (2009) Repeated measures of serum glucose and insulin in relation to postmenopausal breast cancer. Int J Cancer 125:2704–2710PubMedCrossRef

62.

Larsson SC, Mantzoros CS, Wolk A (2007) Diabetes mellitus and risk of breast cancer: a meta-analysis. Int J Cancer 121:856–862PubMedCrossRef

63.

Cantrell LA, Zhou C, Mendivil A et al (2010) Metformin is a potent inhibitor of endometrial cancer cell proliferation-implications for a novel treatment strategy. Gynecol Oncol 116:92–98PubMedPubMedCentralCrossRef

64.

Romero IL, McCormick A, McEwen KA et al (2012) Relationship of type II diabetes and metformin use to ovarian cancer progression, survival, and chemosensitivity. Obstet Gynecol 119:61–67PubMedPubMedCentralCrossRef

65.

Rattan R, Giri S, Hartmann LC, Shridhar V (2011) Metformin attenuates ovarian cancer cell growth in an AMP-kinase dispensable manner. J Cell Mol Med 15:166–178PubMedPubMedCentralCrossRef

66.

Abe R, Yamagishi S (2008) AGE–RAGE system and carcinogenesis. Curr Pharm Des 14:940–945PubMedCrossRef

67.

Hirsch HA, Iliopoulos D, Tsichlis PN et al (2009) Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res 69:7507–7511PubMedPubMedCentralCrossRef

68.

Gotlieb WH, Saumet J, Beauchamp MC et al (2008) In vitro metformin anti-neoplastic activity in epithelial ovarian cancer. Gynecol Oncol 110:246–250PubMedCrossRef

69.

Libby G, Donnelly LA, Donnan PT et al (2009) New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diab Care 32:1620–1625CrossRef

70.

Goodwin PJ, Stambolic V, Lemieux J et al (2011) Evaluation of metformin in early breast cancer: a modification of the traditional paradigm for clinical testing of anti-cancer agents. Breast Cancer Res Treat 126:215–220PubMedCrossRef

71.

Teng JA, Hou RL, Li DL et al (2011) Glargine promotes proliferation of breast adenocarcinoma cell line MCF-7 via AKT activation. Horm Metab Res 43:519–523PubMedCrossRef

72.

Jonasson JM, Ljung R, Talback M et al (2009) Insulin glargine use and short-term incidence of malignancies—a population-based follow-up study in Sweden. Diabetologia 52:1745–1754PubMedCrossRef

73.

Colhoun HM, SDRN Epidemiology Group (2009) Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group. Diabetologia 52:1755–1765CrossRef

74.

Kim HJ, Kwon H, Lee JW et al (2015) Metformin increases survival in hormone receptor-positive, Her2-positive breast cancer patients with diabetes. Breast Cancer Res 17:64PubMedPubMedCentralCrossRef

75.

Oppong BA, Pharmer LA, Oskar S et al (2014) The effect of metformin on breast cancer outcomes in patients with type 2 diabetes. Cancer Med 3:1025–1034PubMedPubMedCentralCrossRef

Titel: Diabetes mellitus and gynecologic cancer: molecular mechanisms, epidemiological, clinical and prognostic perspectives
verfasst von: Nikolaos Vrachnis
Christos Iavazzo
Zoe Iliodromiti
Stavros Sifakis
Andreas Alexandrou
Charalambos Siristatidis
Charalambos Grigoriadis
Dimitrios Botsis
George Creatsas
Publikationsdatum: 01.02.2016
Verlag: Springer Berlin Heidelberg
Erschienen in: Archives of Gynecology and Obstetrics / Ausgabe 2/2016
Print ISSN: 0932-0067
Elektronische ISSN: 1432-0711
DOI: https://doi.org/10.1007/s00404-015-3858-z

Neu im Fachgebiet Gynäkologie und Geburtshilfe

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Diabetes mellitus and gynecologic cancer: molecular mechanisms, epidemiological, clinical and prognostic perspectives